Tinnitus, a widespread global health issue affecting quality of life and mental well-being, now has an innovative solution: Lenire. This at-home device, the first to receive FDA approval for tinnitus treatment, employs bimodal neuromodulation to effectively reduce symptoms. Backed by a large-scale, FDA-compliant clinical trial where 83% of participants recommended it, Lenire has also shown positive outcomes in real-world settings. Over 300 patients at Alaska Hearing and Tinnitus Center experienced a strong response to a hybrid care approach using bimodal stimulation, with the vast majority responding positively at the first and second follow-up assessments.
- Attendees will be able to explain the concept of bimodal neuromodulation as it relates to tinnitus treatment.
- Attendees will be able to summarize results of clinical trials demonstrating use of bimodal neuromodulation to treat tinnitus.
- Attendees will be able to summarize real-world results with the Lenire tinnitus treatment device.
Speakers: Tish Ramirez, Au.D.; Emily McMahan, Au.D.
Moderator: Sam Vaught, Au.D.
